Harvard Bioscience

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Harvard Bioscience reports strong Q4 earnings, eyes China growth

Harvard Bioscience delivered solid financial performance in Q4 2022 with revenue growth and strong margins.
The company faces challenges in supply chain issues and debt reduction but is focused on growth opportunities.
Strategic plans for new product development and improving gross margins are key priorities for future success.

Harvard Bioscience reports strong Q1 earnings, eyes growth opportunities

Harvard Bioscience delivered solid Q1 2023 results with revenue growth, improved margins, and enhanced profitability. While facing challenges in sales organization and market shifts, the company is strategically positioned to capitalize on opportunities for growth through new product offerings and operational efficiencies.

Harvard Bioscience reports mixed Q2 results, eyes growth opportunities

Harvard Bioscience's Q2 2023 performance showed slight revenue decline but notable improvements in margins and profitability.
The company's strengths include new product launches, positive financial metrics, and a promising revenue guidance for 2023.
Challenges include managing discontinued products impact, sales force effectiveness, and profitability.
Opportunities exist in leveraging new products, addressing challenges, and optimizing financial performance drivers.

Harvard Bioscience reports improved margins and profitability in Q3

Harvard Bioscience (HBIO) showed mixed performance in Q3 2023 with revenue decline but improved margins and profitability. The company aims to sustain growth through new product launches and service expansion while managing debt effectively.

Harvard Bioscience reports Q4 results, eyes growth through new products

Harvard Bioscience reported mixed Q4 2023 results with revenue decline in some regions.
The company aims for long-term growth through new products and market expansion.
Challenges include revenue decline in certain regions and maintaining/improving margins.
Opportunities lie in new product launches, partnerships, and market expansion strategies.

Harvard Bioscience faces Q1 revenue dip, eyes second-half turnaround

Harvard Bioscience navigated a tough Q1 marked by revenue declines in key regions and operational challenges. However, the company's focus on new product launches and efficiency in maintaining a strong gross margin are positive indicators. Looking ahead, Harvard Bioscience anticipates a turnaround in the second half of the year with improved margins and overall performance.

Harvard Bioscience reports Q3 revenue decline, eyes growth opportunities

Harvard Bioscience faced revenue decline in Q3 due to China and Asia Pacific weakness but expects stabilization and growth.
Operational improvements and cost reductions are enhancing efficiency and profitability.
New product launches and focus on high-growth areas position the company for incremental growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023.

Harvard Bioscience Announces Third Quarter 2023 Financial Results

HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.

Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023

HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on November 7, 2023, and will hold a conference call to discuss the results at 8:00 a.m.

Harvard Bioscience Schedules Third Quarter 2023 Earnings Conference Call for November 7, 2023 at 8:00 AM ET

Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)

Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research

Harvard Bioscience's Q2 earnings showed a slight miss on EPS and revenue, causing a decline in the stock price. The company is committed to improving its product portfolio and has observed increased traction from new products launched last year. Despite the earnings miss, Harvard Bioscience is still pulling in profit and experiencing growth, with updated guidance for 2023 showing expected revenue increase.

Harvard Bioscience: Looking To Reload After Post-Q2 Earnings Sell-Off

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Thank you for standing by and welcome to Harvard Bioscience's Second Quarter 2023 Earnings Call. [Operator Instructions] I would now like to hand the call over to your host, David Sirois, Director of SEC Reporting.

Harvard Bioscience, Inc. (HBIO) Q2 2023 Earnings Call Transcript

Harvard Bioscience (HBIO) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.05 per share a year ago.

Harvard Bioscience (HBIO) Q2 Earnings and Revenues Lag Estimates

HOLLISTON, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2023.

Harvard Bioscience Announces Second Quarter 2023 Financial Results

HOLLISTON, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Sidoti August Virtual Investor Conference on August 16, 2023. Joining him will be Jennifer Cote, the company's Chief Financial Officer and Treasurer.

Harvard Bioscience to Present at Sidoti Virtual Investor Conference on August 16, 2023

HOLLISTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2023 before the market opens on August 8, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Harvard Bioscience Schedules Second Quarter 2023 Earnings Conference Call for August 8, 2023 at 8:00 AM ET

HOLLISTON, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced that it is set to join the Russell 2000® and Russell 3000 Indexes, according to preliminary membership information posted to the FTSE Russell website. The addition is expected to become effective at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.

Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes

Harvard Bioscience (HBIO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in Harvard Bioscience (HBIO) Should Keep going

Today, we take our first look at medical device concern Harvard Bioscience, Inc. The shares have doubled over the past few months on better-than-expected results and improving cash flow. Can the rally continue? An investment analysis follows in the paragraphs below.

Harvard Bioscience: Rally In Shares Losing Steam

HOLLISTON, Mass., June 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the appointment of Jennifer Cote as the Company's Chief Financial Officer and Treasurer, effective June 19, 2023.

Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

Mettler-Toledo

Waters

The Zacks Instruments - Scientific industry participants like Harvard Bioscience (HBIO), Mettler-Toledo (MTD) and Waters (WAT) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.

3 Instruments Stocks to Watch From a Prospering Industry

InterDigital

MicroStrategy Incorporated

Weave Communications

Investors should consider stocks like Harvard Bioscience (HBIO), MicroStrategy (MSTR), Meta Platforms (META), InterDigital (IDCC), and Weave Communications (WEAV) in their portfolio if they want to outperform the broader market.

5 High-Flying Tech Stocks With Solid Growth Potential

What Makes Harvard Bioscience (HBIO) a Good Fit for 'Trend Investing'

HOLLISTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Micro Cap Virtual Conference taking place on May 10th, 2023.

Harvard Bioscience to Present at Sidoti Micro Cap Virtual Conference May 10th, 2023

Harvard Bioscience's shares are up more than 105% so far this year. The company is seeing strong sales from its equipment to aid in CRISPR gene-editing.

Why Harvard Bioscience Stock Rose This Week

Harvard Bioscience, Inc. (HBIO) Q1 2023 Results - Earnings Call Transcript.

Harvard Bioscience, Inc. (HBIO) Q1 2023 Results - Earnings Call Transcript

HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2023.

Harvard Bioscience Announces First Quarter 2023 Financial Results

Designed to meet the pre-clinical testing needs of CROs, pharma and research laboratories Designed to meet the pre-clinical testing needs of CROs, pharma and research laboratories

Harvard Bioscience Announces Initial Order for Integrated Animal Behavior Monitoring System

HOLLISTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2023 before the market opens on April 25, 2023, and will hold a conference call to discuss the results at 9:00 a.m. Eastern Time.

Harvard Bioscience Schedules First Quarter 2023 Earnings Conference Call for April 25, 2023 at 9:00 AM ET

Harvard Bioscience is seeing strong order growth for its improved product portfolio. Harvard Bioscience has strong expected earnings growth for 2023 and 2024.

Harvard Bioscience: Stock To Rise On Long-Term Growth And Attractive Valuation

HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023.

News for Harvard Bioscience Stock (HBIO)